CN Menu
EN / CN
Resilience
We quickly adapt to changing circumstances, and come out stronger.
Trust
We empower people to take risks, own their decisions, and lead with confidence.
Readmore
Ambition
We set big goals and move fast, always looking for smarter, better ways to make an impact.
Open Communication is Non-Negotiable
No politics, no rank—honest conversations that spark real solutions.
Readmore
Selflessness
We work together, seek the best for Usynova, and turn great ideas into game-changing results.
Readmore
Usynova
To use our knowledge to invent new medicines for patients
Local Innovation, Global Cooperation
Devoted to addressing unsatisfied clinical needs and developing new drugs with independent intellectual property rights
Readmore
Pipeline
Readmore
Core Business
Readmore
Leadership Team
Readmore
Our Value
Readmore
News
Readmore
Nov 23,2023
Usynova Announce a Global Exclusive Licensing Agreement with AstraZeneca for UA022 Targeting KRAS G12D
Readmore
Mar 15,2022
Successful Completion of Phase I Clinical Trial of UA007, Usynova’s New Drug for Gout
Usynova Pharmaceuticals Ltd. (Shanghai) recently announced that its independent-developed new biological agent UA007 successfully completed the phase I clinical trial of gout.
Readmore
Feb 08,2022
Usynova Completes RMB 200 Million Series A Financing, Focusing on the Development of Innovative Drugs for Autoimmune Diseases and Tumors
Readmore
Sep 16,2021
Tee Labs Officially Put into Operation
Readmore
Aug 05,2021
Usynova and Insilico Medicine Announce Strategic Partnership on Accelerating R&D of Small Molecule Innovative Drug with AI
Readmore
祐森健恒生物医药（上海）有限公司 沪ICP备2021025094号-1
技术支持：集锦科技